New antibody-drug conjugates show promise as potential standard for extensive-stage small cell lung cancer at WCLC 2026

The World Conference on Lung Cancer showcased several late‑stage trial updates, with a focus on new therapies for small cell lung cancer, the more aggressive form of the disease.

Antibody‑drug conjugates presented by multiple companies demonstrated response rates that could extend survival beyond the typical one‑year benefit of current chemotherapy, immunotherapy and radiation regimens. Analysts noted the data could shift the treatment paradigm for patients with extensive‑stage disease.

At the same meeting, questions were raised about the reliability of trial results generated in China, prompting discussion among regulators and investors. AstraZeneca also highlighted its own pipeline, drawing additional attention to the evolving landscape of lung cancer treatment.